Mabion SA 2020 AR2
The report details Mabion S.A.'s operations and financial performance for the year 2020, highlighting a strategic shift to register its biosimilar drug MabionCD20 directly on a commercial scale with the EMA. The company completed the validation of the commercial-scale manufacturing process for MabionCD20 and initiated a partnership with Novavax for COVID-19 vaccine technology transfer. Additionally, Mabion successfully implemented and certified an Integrated Management System in accordance with ISO 14001, ISO 45001, and ISO 50001 standards. The company also advanced its R&D portfolio, including progress on biosimilars for denosumab and omalizumab.
Company: Mabion SA
Sector: Manufacturing
Country: Poland
Year: 2020
Type: AR2
Pages: 116
Back to company
Mabion SA
Directors' Report
The report details Mabion S.A.'s operations and financial performance for the year 2020, highlighting a strategic shift to register its biosimilar drug MabionCD20 directly on a commercial scale with the EMA. The company completed the validation of the commercial-scale manufacturing process for MabionCD20 and initiated a partnership with Novavax for COVID-19 vaccine technology transfer. Additionally, Mabion successfully implemented and certified an Integrated Management System in accordance with ISO 14001, ISO 45001, and ISO 50001 standards. The company also advanced its R&D portfolio, including progress on biosimilars for denosumab and omalizumab.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2020
Reporting Period
Jan 1, 2020 - Dec 31, 2020
Fiscal Year
2020
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Materiality Assessment
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Employees